Merck & Co and ALK-Abello are celebrating the US green light for their grass pollen allergy immunotherapy Grastek.
The US Food and Drug Administration has approved Grastek, an allergen extract in a sublingual tablet, for the treatment of Timothy grass pollen-induced allergic rhinitis with or without conjunctivitis. The thumbs-up was expected given that the FDA’s Allergenic Products Advisory Committee voted unanimously to recommend approval at the end of 2013 but it does come with a boxed warning regarding severe allergic reactions.
Read more at: http://www.pharmatimes.com/Article/14-04-15/Merck_Co_gets_FDA_OK_for_allergy_treatment_Grastek.aspx#ixzz2z11s8ydQ
Filed under: FDA 2014, NEW DRUGS Tagged: GRASTEK
